13A-1080802
TW I817041、US、CN、EP pending
Influenza vaccines majorly compose Hemagglutinin (HA) of influenza virus as the main antigen, however, HA easily encounters instability problems, making the produced vaccine reduced in vaccine efficacy and difficult to sustain the long-term storage. By using a structure-guided protein recombination approach, we produced chimeric HAs with improved thermostability and proper immunogenicity. The technique could be applied to other pharmaceutical-related proteins for their stability improvement. We also demonstrated the usage of recombinant baculovirus to display HAs on the insect cell surface for stability assay. Baculoviruses can display functional HAs or influenza neuraminidase (NA) proteins on the viral envelopes. These HA/NA-displayed baculoviruses could also serve as effective vaccine antigens to protect against the influenza virus.
- Produce influenza vaccines with improved thermostability.
- Generation of thermostable antigens by structure-guided recombination.
- Prolong the shelf life of HA vaccines.
- Use baculoviruses to produce HA antigens.
- Presentation of viral antigen on baculovirus as the vaccine.
- Baculoviruses as safe carriers for viral vaccine production.
- Effective vaccine components
- Vaccine antigen stability improvement
- Subunit and carrier influenza vaccine production
- Functional analysis tools for influenza virus HA and NA
Yu-Chan Chao
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Stability Improvement of Hemagglutinin from Influenza Virus